crmd_nt10q.htm
 
       
       
   UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
  
 
       
       
  FORM 12b-25  SEC FILE NUMBER
 
001-34673
       
       CUSIP NUMBER
   NOTIFICATION OF LATE FILING
21900C100
 
 
 
 
(Check one): o  Form 10-K o  Form 20-F o  Form 11-K þ  Form 10-Q o  Form 10-D o  Form N-SAR o  Form N-CSR
                                                                                                                                                                                                                                                                                              
                             
    For Period Ended:   September 30, 2013
       
         
   o  Transition Report on Form 10-K
         
   o  Transition Report on Form 20-F
         
   o  Transition Report on Form 11-K
         
   o  Transition Report on Form 10-Q
         
   o  Transition Report on Form N-SAR
         
    For the Transition Period Ended:
                      
 
 
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
 
 
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
 
PART I — REGISTRANT INFORMATION

CorMedix Inc.
  
Full Name of Registrant
 
   
Former Name if Applicable
 
745 Rte. 202-206. Suite 303
  
Address of Principal Executive Office (Street and Number)
 
Bridgewater, New Jersey 08807
  
City, State and Zip Code
 
 
 
 
 
 
PART II — RULES 12b-25(b) AND (c)
 
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
 
   (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
     
x  (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
   (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
     
 
PART III – NARRATIVE
 
State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
 
(Attach extra Sheets if Needed)
 
The Company requires additional time to complete its valuation of the senior convertible notes and related warrants issued in its July 2013 financing.  The valuation could not be completed without incurring undue hardship and expense. The registrant undertakes the responsibility to file such quarterly report no later than five days after its original date.
 
 
 
PART IV — OTHER INFORMATION

(1)
Name and telephone number of person to contact in regard to this notification
 
 
Randy Milby
  
(908)
    517-9500
 
(Name)
  
(Area Code)
  
(Telephone Number)
 
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
Yes 
 þ
No 
 o  
   
 
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes 
 o
No 
 þ  
 
 
If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
 
 
 
 
 
 
2
 
 
 
CorMedix Inc.
 
(Name of Registrant as Specified in Charter)
 
has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date:  November 14, 2013
    
By:
/s/ Randy Milby
      Name: Randy Milby
      Title:
Chief Executive Officer

 
3